Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Artiva Biotherapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
33.5
0.25
0
Research and development
50.3
50.3
69.5
General and administrative
13.9
17.2
20.3
Operating expenses
64.2
67.5
89.8
Operating income
-30.7
-67.3
-89.8
Other non-operating income
2.02
1.91
5.95
Pre-tax income
-28.6
-65.4
83.9
Income tax
0.07
0
0
Net income
-28.7
-65.4
-83.9
EBITDA
-28.4
-64.9
-87.2
EPS, basic
-35.78
-5.81
-3.43
EPS, diluted
-35.78
-5.81
-3.43
Shares, basic (weighted)
0.8
11.3
24.4
Shares, diluted (weighted)
0.8
11.3
24.4
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
53.5
40.2
26.7
Short-term investments
23.5
145
81.3
Receivables
1.03
0
Other current assets
1.09
3.06
4.59
Total current assets
79.8
189
113
Property, plant and equipment
8.1
6.37
6.62
Lease right-of-use assets
16.5
13.8
10.5
Other non-current assets
0.39
0.27
0.46
Total assets
105
210
131
Accounts payable
0.61
1.12
0.36
Accrued liabilities
8.02
7.39
9.6
Total current liabilities
12.2
12.3
13.1
Lease liabilities
13.3
10.6
7.88
Other non-current liabilities
0.07
0.07
Total liabilities
50.7
22.9
21
Paid-in capital
19
433
440
Retained earnings
-181
-247
-331
Other comprehensive income
0.31
-0.13
0.1
Shareholders' equity
-162
187
110
Total equity
-162
187
110
Total liabilities and equity
105
210
131
Cash flow statement
FY2024
FY2024
FY2025
Net income
-28.7
-65.4
-83.9
Depreciation and amortization
2.27
2.43
2.6
Stock-based compensation
7.05
6.98
6.82
Change in receivables
-0.51
1.03
0
Change in payables
-0.41
0.52
-0.76
Cash from operations
-47.4
-55
-76.8
Capital expenditures
-3.26
-0.64
-2.59
Purchases of investments
-49.5
-176
-44.9
Sales and maturities of investments
56.4
111
Cash from investing
-26
-120
63.4
Stock issued
0.01
167
0
Cash from financing
24.4
162
0.01
Net change in cash
-49
-13.3
-13.3
Free cash flow
-50.7
-55.7
-79.3
Income taxes paid
0.08
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.99 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-26.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-24.6%
Net income / average total assets.
Return on invested capital (ROIC)
-165.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-41.1%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-37.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
117.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
24.2x
Current assets / current liabilities.
Quick ratio
24.0x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
24.0x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.95
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.91
Cash from operations / diluted weighted shares.
Book value per share
$8.82
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.98x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.98x
Market cap / tangible book value, when positive.
FCF yield
-22.5%
Free cash flow / market cap.
Earnings yield
-26.6%
Net income / market cap (the inverse of P/E).
What was Artiva Biotherapeutics, Inc.'s revenue in fiscal 2025?
Artiva Biotherapeutics, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was Artiva Biotherapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $83.9M.
How much free cash flow did Artiva Biotherapeutics, Inc. generate in fiscal 2025?
Cash from operations of $76.8M minus capital expenditures of $2.6M left free cash flow of -$79.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.